A doctor in a white coat holding a pen while making notes on a pad next to his silver laptop A gold scale sits upon a large brown leather lawbook A pile of pills in multipl colors, a mix of hard circular pills and capsules A group of diverse office workers sit around a conference table in a skyscraper with the window behind them looking out over the city
DPL XXXVII Conference Website 

The American Society for Pharmacy Law (ASPL) is an organization of attorneys, pharmacists, pharmacist-attorneys and students of pharmacy or law who are interested in the law as it applies to pharmacy, pharmacists, wholesalers, manufacturers, state and federal government and other interested parties.

ASPL is a non-profit which encourages diversity & inclusion with the Society, regardless of differing backgrounds, perspectives, experiences, orientations, origins, and practice settings. The Society embraces participation and diversity as it leads to advancing our purpose: 

  • Furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues;
  • Communicating accurate legal educational information; and
  • Providing educational opportunities for pharmacists, attorneys, and others who are interested in pharmacy law

Latest News

FDA grants enforcement discretion to compounding six peptides

The Food and Drug Administration has granted enforcement discretion, allowing 503A compounding pharmacies to compound six peptide bulk substances: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. No timeframe was given as to how long this enforcement discretion will last. 

In July, the FDA’s Pharmacy Compounding Advisory Committee voted to recommend these six peptides be added to the 503A Bulks List, which outlines the bulk drug substances that compounding pharmacies can use in creating medications. The committee also rejected adding emideltide to the list.

Pharmacies are still awaiting final rulemaking on these peptides. 

[HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS.]